Given that improvement of T-cell therapy by addition of PD-1 blockade required host endogenous T cells, we postulated that the enhanced efficacy was mediated by endogenous T cell targeting of immunogenic tumor antigens. This evidence concerns the gene PDCD1 and neoplasm.